Itraconazole, Quantitative by LC-MS/MS
Optimize drug therapy and monitor patient adherence.
New York DOH Approval Status
Timing of specimen collection: Pre-dose (trough) draw - At steady state concentration.
Plain Red, Lavender (EDTA), or Green (Sodium or Lithium Heparin).
Separate from cells ASAP or within 2 hours of collection. Transfer 1 mL serum or plasma to an ARUP Standard Transport Tube. (Min: 0.6 mL)
Whole blood. Gel separator tubes, Light Blue (citrate), or Yellow (SPS or ACD solution).
After separation from cells: Ambient: 48 hours; Refrigerated: 48 hours; Frozen: 6 months
Quantitative High Performance Liquid Chromatography-Tandem Mass Spectrometry
Tue, Thu, Sat
Effective August 15, 2011
|Itraconazole (trough) - Localized Infection||Greater than 0.5 µg/mL|
|Itraconazole (trough) - Systemic Infection||Greater than 1.0 µg/mL|
|Hydroxyitraconazole||No therapeutic range established|
Itraconazole is an azole antifungal drug indicated to treat fungal infections. The therapeutic range is based on serum, predose (trough) draw collection at steady-state concentration. The pharmacokinetics of itraconazole are influenced by drug-drug interactions when coadministered with drugs metabolized by cytochrome P450 3A4 enzyme. Itraconazole and hydroxyitraconazole concentrations combined should not exceed 10 µg/mL. Adverse effects may include nausea, abdominal pain, and congestive heart failure.
Laboratory Developed Test (LDT)
|Component Test Code*||Component Chart Name||LOINC|
|0098517||Itraconazole, Quantitative by LC-MS/MS||10989-2|
- Antifungal Serum Level
- itranconazole blood level
- sporanox blood concentration
- Sporanox blood level